•  
 

Fertility preservation survey

 

Chemotherapy treatment may lead to the loss of reproductive organ function, premature ovarian failure or the inability to produce mature eggs for ovulation. It is difficult to reliably predict post-treatment ovarian reserve and there are no reliable incidence figures on infertility following cancer treatment.

 

The aim of this study is to better understand physicians’ knowledge of, and attitudes toward fertility preservation for cancer patients. This information will be published to help fertility treatment providers and oncologists develop optimized fertility preservation care approaches and strategies.

 

Personal data is collected only to ensure the accuracy and authenticity of the clinical data submitted and generated. Personal data will not be published.

 

First and last name
IVF unit name
Email
1. Country
2. Estimated total number of IVF cycles performed by the unit annually
cycles
cycles
cycles
cycles
cycles
cycles
cycles
cycles
cycles
cycles
cycles
cycles
cycles
cycles
cycles
cycles
cycles
cycles
cycles
cycles
3. Do you perform treatment for fertility preservation for cancer patients or do you refer patients to other treatment centers?



4. Please estimate the number of cancer patients treated annually in your clinic for fertility preservation






5. Cancer patients who consult with you for fertility preservation:



6. In your opinion, does the oncologist sufficiently address patient questions on, or inform patients about fertility after cancer treatment?



7. Do you cryopreserve ovarian tissue for fertility preservation?


8. Please estimate the annual number of patients for whom you perform ovarian tissue cryopreservation





9. Who typically pays for fertility preservation treatment for cancer patients?




10. Are you doing in vitro maturation (IVM) for fertility preservation in cancer patients?



11. In patients with malignant hematological diseases, when do you start fertility preservation treatment?




12. Does your unit have differences in treatment protocols based on the type of the malignancy?



13. For fertility preservation treatment in cancer patients, do you use and prefer:




14. Do you use controlled ovarian hyperstimulation protocols for fertility preservation in breast cancer patients?



15. In breast cancer patients do you use FSH to stimulate the ovaries?



16.In breast cancer patients, do you add aromatase inhibitors to the protocol?



17. In the cases in which you use a GnRH antagonist protocol, do you trigger with an agonist?




18 How many cryopreserved patient oocytes would be sufficient for you to recommend that further treatment cycles are not necessary, if the general condition of the patient would allow her to continue cryopreservation therapy?





19. In your opinion, is there any age limit to the fertility preservation procedure?





20. For ovarian stimulation in cancer patients, what drugs do you use?






21. For married or committed couples, what cryopreservation do you recommend?




22. If the patient passes away, what do you do with the oocytes/embryos stored?





23. In your country, in the case of a married couple in which the woman passes away, is it legal to implant the embryos in a surrogate?



24. Would you consider fertility preservation in the following situations? (multiple answers allowed)




25. Do you think that ovarian cryopreservation should be limited to several centers in each country?



26. How would you describe your level of knowledge of ovarian tissue cryopreservation for fertility preservation?




27. How would you describe your level of knowledge of oocyte cryopreservation for fertility preservation?




28. In your country, are there any local/national guidelines on fertility preservation for cancer patients?



29. Statement? National guidelines on fertility preservation for cancer patients are useful/needed.



30. Statement? Fertility preservation is a high priority for me to discuss with newly diagnosed cancer patients.



31. Statement? Treating the primary cancer is more important than fertility preservation.



32. Statement? Cryopreservation of ovarian tissue is still an experimental procedure.



33. Statement? The success rate of fertility preservation is not yet good enough to make it an available option.



34. Were there pregnancies in your center in the following situations? (multiple answers allowed)





35. The pregnancy rate after oocyte cryopreservation in cancer patients is not yet known because:




I have read HCP RESPONDENT PhV STATEMENT

In accordance with the European Pharmaceutical Market Research Association (EphMRA) Code of Conduct and European Medicines Agency good pharmacovigilance practice guidelines, it is our responsibility to report to our client any adverse events, product quality complaints or reports of drug exposure during pregnancy, on our client’s products that become known to us when conducting healthcare market research. Although what is otherwise recorded during this survey will be treated in confidence, should an adverse event (as defined in the Code of Conduct), product quality complaint or reports of drug exposure during pregnancy in a specific patient, or group of patients, be mentioned, we are required to collect this information and report it to the client, even if the event has already been reported to the national health authorities.

To fulfil their responsibilities, for any adverse event / product quality complaint / exposure during pregnancy report recorded, the client has requested that they can approach you for further information following completion of the interview, if it is considered appropriate or necessary to do so.